Mitoxantrone in multiple sclerosis.
Neuhaus
Oliver
O
Department of Neurology, Heinrich Heine University, Düsseldorf, Germany.
Kieseier
Bernd C
BC
Hartung
Hans-Peter
HP
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D007107:Immune System / Q000187:drug effects / Q000276:immunology; D007155:Immunologic Factors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D008942:Mitoxantrone / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D007155:Immunologic Factors; D008942:Mitoxantrone